|Day Low/High||173.01 / 175.53|
|52 Wk Low/High||86.88 / 171.69|
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
JAZZ has been upgraded to a buy recommendation by TheStreet's Quant Ratings service.
These names are showing both technical and quantitative deterioration.
Let's review the charts and indicators of this Dublin-based biopharmaceutical.
Two reasons to buy a stock are better than one. Right?
These 'Bearish Bets' are showing both technical and quantitative deterioration.
The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.
But we could see more volatility in the market.
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.